NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

NCT06945419

CompletedPhase 1

Sponsor: Eli Lilly and Company

Conditions: Healthy, Overweight, Obesity, Type 2 Diabetes

Interventions: LY4086940, Placebo, LY4086940

Countries: United States, Singapore

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Have no significant body weight change for the 3 months prior to screening

Part A and Part E:

* Are considered healthy
* Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening

Part B:

* Have a BMI of 27 to 45 kg/m2 at screening

Part C:

* Have a BMI of 25 to 45 kg/m2 at screening

Part D:

* Have type 2 diabetes
* Have hemoglobin A1C (HbA1c) ≥6.5% and ≤10.5% at screening
* Have a BMI of 27 to 45 kg/m2 at screening

Exclusion Criteria:

* Have had an acute cardiovascular condition within the past 6 months prior to screening
* Have liver disease or pancreatitis
* Have used medications for weight loss within the 3 months prior to screening

Parts A, B, C, E:

* Have any form of diabetes

Part D:

* Have type 1 diabetes

Locations (5)

Daytona Beach, Florida, United States
Miami, Florida, United States
Dallas, Texas, United States
San Antonio, Texas, United States
Singapore, Singapore